Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation

Elliott, Robert B.; Escobar, Livia; Tan, Paul; Muzina, M.; Zwain, Sahar; Buchanan, Christina M.

doi:10.1111/j.1399-3089.2007.00384.x

Cited by 371 publications

(266 citation statements)

References 11 publications

Supporting

Mentioning

255

Contrasting

Unclassified

Order By: Relevance

“…In this technology, donor islets are coated with a semipermeable membrane that blocks cells and large molecules of the host immune system but is permeable to essential nutrients, glucose, and insulin. Microencapsulation has been shown to be feasible in various experimental systems (14)(15)(16)(17)(18)(19) and in pilot clinical trials (20). However, the limited lifetime of microencapsulated islets and the large islet tissue volume required are obstacles that must be overcome to make this approach clinically viable.…”

mentioning

confidence: 99%

Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist

Ludwig

Rotem

Schmid

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

169

129

View full text Add to dashboard Cite

Islet transplantation is a feasible therapeutic alternative for metabolically labile patients with type 1 diabetes. The primary therapeutic target is stable glycemic control and prevention of complications associated with diabetes by reconstitution of endogenous insulin secretion. However, critical shortage of donor organs, gradual loss in graft function over time, and chronic need for immunosuppression limit the indication for islet transplantation to a small group of patients. Here we present a promising approach to address these limitations by utilization of a macrochamber specially engineered for islet transplantation. The s.c. implantable device allows for controlled and adequate oxygen supply and provides immunological protection of donor islets against the host immune system. The minimally invasive implantable chamber normalized blood glucose in streptozotocin-induced diabetic rodents for up to 3 mo. Sufficient graft function depended on oxygen supply. Pretreatment with the growth hormone-releasing hormone (GHRH) agonist, JI-36, significantly enhanced graft function by improving glucose tolerance and increasing β-cell insulin reserve in rats thereby allowing for a reduction of the islet mass required for metabolic control. As a result of hypervascularization of the tissue surrounding the device, no relevant delay in insulin response to glucose changes has been observed. Consequently, this system opens up a fundamental strategy for therapy of diabetes and may provide a promising avenue for future approaches to xenotransplantation. treatment of diabetes | immune isolation | beta cells

show abstract

mentioning

confidence: 99%

Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist

Ludwig

Rotem

Schmid

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

169

129

View full text Add to dashboard Cite

show abstract

“…However, multiple factors can influence alginate-based capsule stability after transplantation, such as the implantation site and capsule composition (30). Retrieval of live encapsulated porcine islets from a patient 9.5 years after xenotransplantation has been reported (31). More importantly, clinical trials of several alginate-based encapsulation systems have been or are being conducted, such as those with GLP-1 CellBeads ® (alginate microcapsules containing allogenic mesenchymal cells which are genetically modified to secrete glucagon-like peptide-1 [GLP-1] for the treatment of stroke patients with space-occupying intracerebral hemorrhage; the study has been terminated) (32) and NTCELL ® (alginate-encapsulated porcine choroid plexus cells for xenotransplantation in patients with Parkinson’s disease; a Phase I/IIa clinical trial was completed in 2015 with promising results, and a Phase IIb study began in 2016) (33).…”

Section: Bioencapsulation Materials and Methodsmentioning

confidence: 99%

Bioencapsulation Technologies in Tissue Engineering

Majewski

Zhang

et al. 2016

Journal of Applied Biomaterials & Functional Materials

View full text Add to dashboard Cite

Bioencapsulation technologies have played an important role in the developing successes of tissue engineering. Besides offering immunoisolation, they also show promise for cell/tissue banking and the directed differentiation of stem cells, by providing a unique microenvironment. This review describes bioencapsulation technologies and summarizes their recent progress in research into tissue engineering. The review concludes with a brief outlook regarding future research directions in this field.

show abstract

“…The product, called DIABECELL, is currently in late-stage clinical trials in several countries. Patients implanted with the cells have survived more than nine years without evidence of immune rejection or infection 3 .…”

Section: Long Historymentioning

confidence: 99%

New life for pig-to-human transplants

Reardon¹

2015

Nature

View full text Add to dashboard Cite

Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation

Abstract: This form of xenotransplantation treatment has the potential for sustained benefit in human type 1 diabetics.

Cited by 371 publications

References 11 publications

Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist

Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist

Bioencapsulation Technologies in Tissue Engineering

New life for pig-to-human transplants

Contact Info

Product

Resources

About